GlassScriptPhysician profile
Hernan S Reyes
NPI 1386868826
$5,814.27
in general payments reported to CMS, 2019-2025
26 companies · $16.18 in 2025
The $16.18 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,205 · 2020: $1,584 · 2021: $1,390 · 2022: $465 · 2023: $65.30 · 2024: $89.42 · 2025: $16.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,084.92 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $731.38 | 2019-2022 | |
| Glaxosmithkline, LLC. | $648.94 | 2019-2021 | |
| Novo Nordisk INC | $445.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $356.91 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $354.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $325.91 | 2019-2022 | |
| Abbvie INC. | $254.03 | 2020-2024 | |
| Sunovion Pharmaceuticals INC. | $244.94 | 2019-2021 | |
| Mylan Specialty L.P. | $217.96 | 2021-2023 | Yupelri |
| Lilly USA, LLC | $203.57 | 2019-2021 | |
| Amgen INC. | $143.71 | 2020-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $120.08 | 2022-2024 | |
| Pfizer INC. | $119.72 | 2020-2021 | |
| Allergan, INC. | $96.37 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $93.82 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $82.77 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $60.16 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.60 | 2019-2020 | |
| Roche Diabetes Care, INC. | $44.29 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.80 | 2024-2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $22.59 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.27 | 2020 | |
| Genentech USA, INC. | $18.70 | 2019 | |
| Exact Sciences Corporation | $18.42 | 2024 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $12.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hernan Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.